In a phase I/II trial, allogeneic mesenchymal stem cell infusions for frailty had acceptable safety and signs of functional improvement (small sample).
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).